American epigenetic-editing firm based in Alameda, California. Co-founded by Jennifer Doudna, the Nobel-prizewinning co-inventor of CRISPR. Its editing platform, ELXR, is a refinement of CRISPR that employs a smaller, nimbler enzyme called CasX rather than the standard Cas9. Benjamin Oakes, another co-founder, is the firm's chief executive.
Scribe's lead target is a gene called PCSK9, which encodes a liver protein that reduces the breakdown of cholesterol-rich low-density lipoproteins (LDLs). Too many LDLs in the bloodstream can lead to atherosclerosis, the main cause of heart attacks and strokes, which kill around 17m people a year. Scribe's proposed treatment is an epigenetic edit that turns down the volume on PCSK9 and thus ups the destruction of LDLs—a one-off dose rather than the daily round of pills currently prescribed. Clinical trials were expected to begin in the summer of 2026.
"Eat, drink, and be merry, for tomorrow you may work."